Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ligand Pharmaceuticals Incorporated - Common Stock (NQ:LGND)

256.37 -18.51 (-6.73%)
Streaming Delayed Price Updated: 10:07 AM EDT, Jun 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ligand Pharmaceuticals Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More ↗
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga
News headline image
Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Roth Capital Maintains Buy Rating for Ligand Pharmaceuticals: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Tesla To $175? Here Are 10 Other Price Target Changes For Friday ↗
Oppenheimer cut CarMax, Inc. (NYSE: KMX) price target from $100 to $75. . Oppenheimer analyst Brian Nagel maintained an Outperform rating on the stock. CarMax shares fell 1.3% to $56.47 in pre-market... 
Via Benzinga
News headline image
Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Says ↗
Credit Suisse initiated coverage on OmniAb Inc (NASDAQ: OABI) with an Outperform rating and a price target of $13. 
Via Benzinga
News headline image
Ligand Pharma Issues Mixed Guidance For FY23 ↗
At its Investor and Analyst Day event, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided an overview of Ligand's corporate structure and business following the successful spin-off of its... 
Via Benzinga
News headline image
Ligand Provides Highlights from its Investor and Analyst Day Event
From Ligand Pharmaceuticals
Via Business Wire
News headline image
Ligand Pharmaceuticals Names Director Todd C. Davis as CEO
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand to Hold Investor and Analyst Day on December 13
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Reports Third Quarter 2022 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Earnings Outlook For Ligand Pharmaceuticals ↗
Ligand Pharmaceuticals (NASDAQ:LGND) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that Ligand... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers Monopar Therapeutics (NASDAQ:MNPR) shares increased by 53.0% to $4.09 during Wednesday's pre-market session. The company's market cap stands at $52.0 million. 
Via Benzinga
News headline image
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know ↗
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the... 
Via Benzinga
News headline image
Ligand Announces Completion of OmniAb Spin-Off
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Distribution of OmniAb Complete and Business Combination Closed
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand to Report Third Quarter Financial Results on November 7
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
OmniAb Business Combination Approved by APAC Shareholders
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Janssen Scores Conditional Approval For Multiple Myeloma Treatment In Pretreated Patients ↗
 
Via Benzinga
News headline image
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Pharmaceuticals: Q2 Earnings Insights ↗
  Ligand Pharmaceuticals (NASDAQ:LGND) reported its Q2 earnings results on Monday, August 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Ligand Pharmaceuticals... 
Via Benzinga
News headline image
Ligand Reports Second Quarter 2022 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand to Report Second Quarter Financial Results on August 8
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Barclays Maintains Overweight Rating for Ligand Pharmaceuticals: Here's What You Need To Know ↗
Barclays has decided to maintain its Overweight rating of Ligand Pharmaceuticals (NASDAQ:LGND) and lower its price target from $165.00 to $157.00. Shares of Ligand Pharmaceuticals are trading up 1.79%... 
Via Benzinga
News headline image
Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
10 Biggest Price Target Changes For Monday ↗
Needham cut the price target on Carvana Co. (NYSE: CVNA) from $121 to $80. Carvana shares rose 11.3% to $42.71 in pre-market trading. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.